Copenhagen, 10 November 2010 - NeuroSearch A/S (NEUR) today informed that the
company's interim report for the third quarter 2010 will be released on 18
November 2010. The report is expected to be released before the opening of the
NASDAQ OMX Copenhagen Stock Exchange.

Conference call:
On the day of release at 11 am Copenhagen time (10 am London time, 5 am New
York time), the Q3 2010 interim report will be presented at a conference call.
Participating in the call will be CEO Patrik Dahlen, Vice President & CFO Anita
Milland and Vice President and Director of Investor & Capital Market Relations
Hanne Leth Hillman. The conference call will be conducted in English and the
dial-in numbers are: UK and International +44 207 509 5139, US +1 718 354 1226
and DK +45 3271 4767.

Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103


About NeuroSearch
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel drug to treat obesity.

NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery and development alliances with Janssen Pharmaceutica
and Eli Lilly as well as a licence collaboration with Abbott. Further,
NeuroSearch has equity interests in a number of private companies in the Life
Science industry.